The 36-month beta value for TRIB is also noteworthy at 1.39. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TRIB is 7.37M, and at present, short sellers hold a 0.16% of that float. The average trading volume of TRIB on June 17, 2024 was 35.97K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TRIB) stock’s latest price update
The stock of Trinity Biotech Plc ADR (NASDAQ: TRIB) has decreased by -19.65 when compared to last closing price of 3.46.Despite this, the company has seen a gain of 32.38% in its stock price over the last five trading days. globenewswire.com reported 2024-06-10 that DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024.
TRIB’s Market Performance
Trinity Biotech Plc ADR (TRIB) has experienced a 32.38% rise in stock performance for the past week, with a 81.70% rise in the past month, and a 24.11% rise in the past quarter. The volatility ratio for the week is 25.45%, and the volatility levels for the past 30 days are at 11.97% for TRIB. The simple moving average for the past 20 days is 42.86% for TRIB’s stock, with a 16.71% simple moving average for the past 200 days.
Analysts’ Opinion of TRIB
ROTH Capital gave a rating of “Buy” to TRIB, setting the target price at $20 in the report published on July 29th of the previous year.
TRIB Trading at 50.02% from the 50-Day Moving Average
After a stumble in the market that brought TRIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.45% of loss for the given period.
Volatility was left at 11.97%, however, over the last 30 days, the volatility rate increased by 25.45%, as shares surge +77.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.97% upper at present.
During the last 5 trading sessions, TRIB rose by +32.38%, which changed the moving average for the period of 200-days by -28.72% in comparison to the 20-day moving average, which settled at $2.01. In addition, Trinity Biotech Plc ADR saw 29.60% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TRIB
Current profitability levels for the company are sitting at:
- -0.46 for the present operating margin
- 0.32 for the gross margin
The net margin for Trinity Biotech Plc ADR stands at -0.38. The total capital return value is set at -0.38. Equity return is now at value -1967.61, with -37.35 for asset returns.
Based on Trinity Biotech Plc ADR (TRIB), the company’s capital structure generated 1.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.2. The debt to equity ratio resting at -3.3. The interest coverage ratio of the stock is -3.3.
Currently, EBITDA for the company is -13.48 million with net debt to EBITDA at -6.25. When we switch over and look at the enterprise to sales, we see a ratio of 1.71. The receivables turnover for the company is 3.22for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.02.
Conclusion
In summary, Trinity Biotech Plc ADR (TRIB) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
